Is Lanreotide Really Useful in High Output Stoma? Comparison between Lanreotide to Conventional Antidiarrheal Treatment Alone.

Fiche publication

Date publication

août 2020

Journal

Journal of investigative surgery : the official journal of the Academy of Surgical Research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MEYER Nicolas , Pr ORTEGA DEBALLON Pablo , Pr ROHR Serge , Dr ROMAIN Benoit , Dr LAKKIS Zaher , Pr BRIGAND Cécile

Tous les auteurs :
Mesli Y, Holterbach L, Delhorme JB, Lakkis Z, Ortega-Deballon P, Deguelte S, Rohr S, Brigand C, Meyer N, Romain B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32746647

Résumé

The incidence of high-output stoma (HOS) was reported to be approximately 3 to 16% in the literature, and HOS can cause dehydration. This complication is often severe enough to warrant hospital readmission and may result in renal failure. The aim of this study was to show a decrease of 50% in ileostomy output in the experimental arm using lanreotide treatment.